{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pharmacogenetic+testing&page=2", "query": { "intervention": "pharmacogenetic testing", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pharmacogenetic+testing&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T12:46:01.560Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01192815", "title": "Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "gene expression analysis", "type": "OTHER" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "biopsy", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" }, { "name": "polymorphism analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 2, "start_date": "2011-01", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-09-24T12:46:01.560Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192815" }, { "nct_id": "NCT03370718", "title": "Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Carcinoma in the Adrenal Cortex", "Stage III Adrenal Cortex Carcinoma AJCC v8", "Stage IV Adrenal Cortex Carcinoma AJCC v8", "Unresectable Adrenal Cortex Carcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacokinetic Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-02-26", "completion_date": "2024-01-12", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-09-24T12:46:01.560Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03370718" }, { "nct_id": "NCT03537547", "title": "Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder", "Depression", "Depressive Disorder", "Depressive Episode", "Depression, Unipolar" ], "interventions": [ { "name": "GeneSight Psychotropic test", "type": "OTHER" }, { "name": "FDA-approved antidepressant or antipsychotic treatment", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2018-05-04", "completion_date": "2019-08-19", "has_results": false, "last_update_posted_date": "2020-06-05", "last_synced_at": "2026-09-24T12:46:01.560Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03537547" }, { "nct_id": "NCT04736472", "title": "Implementing Pharmacogenetic Testing in Gastrointestinal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastrointestinal Cancer" ], "interventions": [ { "name": "Pharmacogenetic test", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 552, "start_date": "2021-03-26", "completion_date": "2024-10-09", "has_results": true, "last_update_posted_date": "2025-06-06", "last_synced_at": "2026-09-24T12:46:01.560Z", "location_count": 3, "location_summary": "Lancaster, Pennsylvania • Philadelphia, Pennsylvania", "locations": [ { "city": "Lancaster", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04736472" }, { "nct_id": "NCT02581930", "title": "Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Recurrent Cutaneous Melanoma", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2016-12-16", "completion_date": "2021-09-09", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-24T12:46:01.560Z", "location_count": 13, "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02581930" }, { "nct_id": "NCT00245063", "title": "AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer" ], "interventions": [ { "name": "cediranib maleate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-03", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2014-10-02", "last_synced_at": "2026-09-24T12:46:01.560Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00245063" }, { "nct_id": "NCT01334177", "title": "TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Tongue Cancer" ], "interventions": [ { "name": "TLR8 agonist VTX-2337", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2011-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-03-05", "last_synced_at": "2026-09-24T12:46:01.560Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01334177" }, { "nct_id": "NCT01970774", "title": "Medication Therapy Management With Pharmacogenetic Testing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pharmacogenetics", "Medication Therapy Management" ], "interventions": [ { "name": "MTM with PGx", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2013-11", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2015-04-20", "last_synced_at": "2026-09-24T12:46:01.560Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01970774" }, { "nct_id": "NCT04630093", "title": "Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pharmacogenetic Testing" ], "interventions": [ { "name": "Panel-based pharmacogenetic genotyping", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 100, "start_date": "2021-05-13", "completion_date": "2022-06-22", "has_results": true, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-09-24T12:46:01.560Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04630093" }, { "nct_id": "NCT04176172", "title": "Optimizing Tobacco Use Treatment for PLWHA", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV/AIDS", "Nicotine Dependence" ], "interventions": [ { "name": "Varenicline", "type": "DRUG" }, { "name": "Nicotine patch", "type": "DRUG" }, { "name": "Standard treatment", "type": "BEHAVIORAL" }, { "name": "Standard treatment + Managed Problem Solving (MAPS) adherence intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2020-02-17", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-24T12:46:01.560Z", "location_count": 2, "location_summary": "Chicago, Illinois • Philadelphia, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04176172" } ] }